Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension
Clinical trial NCT03512314 · COMPLETED
Trial details
- NCT number
- NCT03512314
- Sponsor
- AB2 Bio Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-24
- Primary completion
- 2024-04-08
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.